Aravax, a clinical-stage biotechnology company, has appointed Aled Williams as Chief Business Officer (CBO) to drive its international expansion, particularly in the development of PVX108, a next-generation immunotherapy for peanut allergy. The appointment, effective immediately, follows the establishment of Aravax's UK subsidiary at the Oxford Science Park.
Strategic Focus on International Growth and Partnerships
Williams's role will encompass creating partnership opportunities for Aravax's portfolio and refining the company's platform and asset strategy. With over 25 years of experience in the biotechnology and pharmaceutical sectors, Williams has held senior positions at various European biotech companies, including CEO of Enthera Pharmaceuticals and CBO of PolyNeuron Pharmaceuticals AG. His pharma experience includes Shire Pharmaceuticals, Bristol Myers-Squibb, Novartis and Hoffman-La Roche.
PVX108: A Targeted Immunotherapy for Peanut Allergy
PVX108, Aravax's lead product, is currently in Phase 2 clinical trials. It is designed as a precision immunotherapy containing a mixture of synthetic peptides targeting the T cells that drive peanut allergy. The therapy is engineered to avoid triggering acute allergic reactions, offering a safer and more convenient treatment option with monthly intradermal administration.
Williams stated, "Food allergy is a rapidly growing and life-threatening problem in countries around the world and so I am hugely excited to be joining Aravax to expand its international outreach. PVX108 is designed to provide safer and more targeted treatment of peanut allergy and has the potential to be a life-changing therapy for patients and their families."
Executive Perspectives on the Appointment
Dr. Pascal Hickey, CEO of Aravax, emphasized the significance of Williams's appointment, stating, "Aled is a highly-respected and experienced biotech and pharma leader, and his appointment is another significant step in our Company’s development as we continue to drive forward our Phase 2 program for PVX108 in peanut allergy and build the capabilities and international platform we need to make our treatments a reality for patients."
Aravax is focused on revolutionizing the treatment of food allergies with safe and convenient next-generation specific immunotherapies. The company's technology aims to reset the immune system to tolerate specific allergens without causing allergic reactions during treatment.
